TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Objective ocular torsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morbidity and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Communication and Attitudinal Self-Efficacy for cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Needs of Health Information for the patients with Gynecological Cancer
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: sensitivity to diagnose HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristic Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular arrhythmias recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA < 400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA < 75 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity degree of muscular discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Widespread pressure pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of GC1102
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Unmedicated Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Mean Number of IOP-Lowering Medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sagittal spinal alignment and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injury risk assessment
Endpoint domain: Adverse events/effects
Primary endpoint: gait evaluated by Rivermead Mobility Index (RMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of ERCP biliary cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidences of adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Moderate-to-vigorous physical activity (MVPA) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in carotid mean vessel wall area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Men's understanding that prostate cancer screening requires a decision
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Men's knowledge about prostate cancer and prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Men's participation in the decision about prostate cancer screening with their clinician at their preferred level
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Serum IL-6 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of metastases development
Endpoint domain: Mortality/survival
Primary endpoint: Systolic Time Intervals (STI) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological risk factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of documented responses/actions to alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vomiting and nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response Rate (Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Intensity of Bone Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response rate of CD19 CAR-T treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% Improvement From Baseline in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Length of inpatient hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With All - Cause Mortality Through Day 42
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Transcranial magnetic stimulation (TMS) resting motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resting-state electroencephalogram (EEG) beta band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of FES Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP/LP Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Patient preference for hepatic embolization approach
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: In-segment minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weekly urticaria activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in smoking urges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in working memory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colonoscopy preparation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acne Scar Improvement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change scores for depressive symptoms using Beck Depression Scale (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change scores for anxiety symptoms using Generalized Anxiety Disorder (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change scores for functional health and well being using the 12-Item Short Form Health Survey (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change scores for depressive symptoms using Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ability to evaluate ureteric jets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC0-30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HBV DNA below detection limit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of ≥grade 2 radiation pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: mean VAS at 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fibrinolytic degradation rate of formed clots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with high concordance between Bispectral Index and NeuroSENSE indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstetric Anal Sphincter injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Child mortality - fetal loss
Endpoint domain: Mortality/survival
Primary endpoint: Child mortality - stillbirths
Endpoint domain: Mortality/survival
Primary endpoint: Child mortality - early infant death
Endpoint domain: Mortality/survival
Primary endpoint: Heart Failure Risk Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Classification of adipose tissue as healthy or inflamed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted Mean TNSS (Sneeze, Itch, Rhinorrhoea and Nasal Blockage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 4 nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of the lumbar vertebrae L1-L4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in average daily frequency of moderate or severe attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral metabolic rate of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of myocellular insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving Less Than 20 HIV RNA Copies Per ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of renal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correlation between eGFR and mGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient On-Study Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disease activity levels (low, moderate, high)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of adverse events related to the infusion of anti-SARS-CoV-2 immunoglobulin
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of viral RNA evaluated by RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in Stroke and Aphasia Quality of Life (SAQOL-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical health and wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Health and wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: occurrence of catheter-related thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrence of major-bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in DAS28(CRP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year high-grade-relapse-free (HGRF) rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in parameters associated with dry eye syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parameters associated with meibomian gland dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of persistent sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Hyperinsulinemic-Euglycemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Assessment of cyclooxygenase 2 protein (COX-2), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) as physiological pain regulators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meal Tolerance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biomarkers of glucoregulatory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Digital radiography of the implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death, myocardial infarction, or repeat revascularization within 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Death, myocardial infarction, or severe myocardial ischemia leading to urgent repeat percutaneous coronary intervention or urgent coronary artery bypass surgery within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Response rate to PROMITIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drool quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB Disease-free Survival at 12M
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Participants With Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative probability of pregnancy through one year
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence and incidence rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative probability of early discontinuation through one year
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of 30-Day combined rate of events
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Success of transShield EPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Human milk intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of R0 Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response to antiviral therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in levels of school time physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of blood parameters profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genomic compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Albumin Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peripheral Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatitis A Virus (HAV) Seroconversion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inspiratory and expiratory oesophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory and expiratory transpulmonary pressure during laparoscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory and expiratory transpulmonary pressure during different positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual relative change in uterine bleeding scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Antistreptolysin O levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Deoxyribonuclease B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Basal Ganglia Antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of neonates developed retinopathy of prematurity
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hours to resolution of ketoacidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hours to achieve blood glucose less than 200mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of dialysis complicated by hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first occurrence of a Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Time to recovery of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic profiles of endogenous insulin and Insulin Aspart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline in phagocytosis of gram-negative bacteria by neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in phagocytosis of gram-negative bacteria by monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in interleukin-1 receptor antagonist secretion in response to lipopolysaccharide stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in interleukin-1-beta secretion in response to lipopolysaccharide stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success of the surgical strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in SCORE (10 Year Risk for Fatal Cardiovascular Event)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Problem Areas in Diabetes Survey - Parent Revised (PAID-PR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Center for Epidemiologic Studies - Depression Scale Revised (CESD-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttraumatic Stress Checklist- Civilian Version (PCL-C) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hookah Tobacco Initiation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hookah Tobacco Use Frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hookah Tobacco Cessation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical examination and laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of low-dose CTC for polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tuberculosis case detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total x-ray time and dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects with treatment-related adverse events following a single oral dose of AF-130
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with treatment-related adverse events following multiple oral doses of AF-130
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Tumor Progression (TTP) of Targeted Lesions
Endpoint domain: Mortality/survival
Primary endpoint: Morphologic response (CR + CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in number of days with headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of days with shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective results in conservative and operative treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective results in operative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent diffusion coefficient (ADC) quantification of scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-hour glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean post-prandial glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Composition parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Profile-aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes